Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Nanoparticle encapsulation improves bioavailability of leukemia drug

Busulfan, which belongs to a family of drugs known as alkylating agents, is used to treat hematological malignancies, including chronic myelogenous leukemia.

9 Oct 2006

UIC receives $20 million NCI grant to research blood disorders

A $19.6 million National Cancer Institute grant has been awarded to the University of Illinois at Chicago College of Medicine to advance basic and clinical research for incurable blood disorders.

6 Sep 2006

Turning the immune system against cancer

Medicine can now prevent a host of diseases with a mere shot of vaccine. Polio and smallpox are almost non-existent, and mumps and chicken pox are rarely seen nowadays.

4 Aug 2006

Smart cancer drug on sale in the UK

A new "smart" cancer drug will be available to patients in Britain today which works by deploying two chemical 'bullets' that attack specific molecular targets, starving tumours of nutrients and inhibiting the enzyme that signals cells to multiply.

31 Jul 2006

Gleevec may cause heart problems

Gleevec, the wildly successful poster-child of a new generation of cancer drugs aimed at specific targets in the cancer cell, can be dangerous to the heart.

24 Jul 2006

FDA grants accelerated approval for Sprycel (dasatinib)

FDA grants accelerated approval for Sprycel (dasatinib), a new oral treatment for patients with chronic myeloid leukemia (CML),

29 Jun 2006

New leukemia drug gives renewed hope to those battling drug resistance to the disease

New research offers hope for victims of chronic myeloid leukemia (CML) battling drug resistance to the disease.

18 Jun 2006

Dasatinib offers new options for leukemia patients

Dasatinib, an experimental drug under development by Bristol-Myers Squibb, reverses the signs and symptoms of patients whose chronic myeloid leukemia has failed to respond to Gleevec, which is considered the standard of treatment for the disorder.

14 Jun 2006

Gleevec strangles drug-resistant, metastatic prostate cancer

A medication used to treat other types of cancer strangles drug-resistant, metastatic prostate cancer by cutting off its blood supply, researchers from The University of Texas M. D. Anderson Cancer Center report in the June 7 issue of the Journal of the National Cancer Institute.

7 Jun 2006

Long-term benefits of imatinib for patients newly diagnosed with chronic myelogenous leukemia

The overall survival of most people with chronic myelogenous leukemia (CML) treated with imatinib (Gleevec, STI-571) is extremely high and the relapse rate is quite low, according to new data from a study out of the Oregon Health & Science University Cancer Institute.

6 Jun 2006

Study confirms Gleevec's long-term benefits in treating advanced gastrointestinal stromal tumors

People with advanced gastrointestinal stromal tumors (GIST) who take Gleevec (imatinib) for prolonged periods continue to benefit from the drug, according to a five-year study by Oregon Health & Science University Cancer Institute researchers.

6 Jun 2006

Cancer treatment interferes with bone development

According to researchers in the U.S. the cancer drug Gleevec (imatinib), which has dramatically improved survival prospects for some cancer patients, can interfere with bone development.

11 May 2006

Promising chemo, therapeutic viruses, cutting-edge surgery debut at M. D. Anderson Cancer Center

Brain tumor specialists at The University of Texas M. D. Anderson Cancer Center are poised on the brink of a new era.

10 May 2006

Finding indicate why some kinds of Leukemia are more aggressive than others

New clues to why some kinds of leukemia are more aggressive and deadly than others are coming from research examining the types of genetic damage that allow some blood cells to grow out of control, scientists report.

28 Apr 2006

Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia

23 Apr 2006

Dasatinib provides significant benefit in chronic myeloid leukemia patients resistant to Gleevec

A study led by researchers from the Howard Hughes Medical Institute has found that dasatinib provides significant benefit in chronic myeloid leukemia (CML) patients resistant to Gleevec. (imatinib), according to a study presented during the 97th Annual Meeting of the American Association for Cancer Research.

11 Apr 2006

ChemGenex Pharmaceuticals receives U.S. orphan drug designation for Ceflatonin

ChemGenex Pharmaceuticals has announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug status for the company's most advanced drug, Ceflatonin, for the treatment of chronic myeloid leukemia (CML).

21 Mar 2006

New way to study proteins in live cells

For the first time, Johns Hopkins researchers were able to easily jumpstart the activity of a well-known cancer protein in live cells with a small molecule, a strategy that pinpointed key players in the cancer process and can be used to determine new therapeutic targets.

9 Mar 2006

Genzyme launches test to monitor Gleevec resistance

Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).

13 Feb 2006

Gene mapping project promises new targeted cancer therapies

Government researchers in the United States have this week launched a pilot project to find all the little genetic changes that cause cancer in the hope it will lead to a whole new world of targeted cancer therapy.

14 Dec 2005